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Autoimmune pancreatitis / IgG4-associated cholangitis and
primary sclerosing cholangitis – Overlapping or separate diseases?q
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2Institute of Hepatology, University College London, London, UK
3Department of Gastroenterology and Hepatology, The John Radcliﬀe Hospital, Oxford, UKAutoimmune pancreatitis is a recently described ﬁbroinﬂammatory disease which is characterised by raised serum levels
of IgG4 (in >70% of cases), and an IgG4-positive lymphoplasmacytic tissue inﬁltrate. A favourable and rapid clinical
response to oral steroid therapy is often seen. Biliary involvement is common, and the term IgG4-associated cholangitis
has recently been coined. The cholangiographic appearances of IgG4-associated cholangitis and primary sclerosing cho-
langitis can be diﬃcult to diﬀerentiate. Moreover, raised levels of serum IgG4 have been recently found in 9% of patients
with primary sclerosing cholangitis (a much higher frequency than for other gastrointestinal diseases), and those with
raised levels appear to progress more rapidly to liver failure. Here we review the similarities and diﬀerences between
the biliary disease in autoimmune pancreatitis and primary sclerosing cholangitis, and address the issue of disease overlap.
Improvements in understanding the relationship between these conditions might lead to an enhanced understanding of the
aetiopathogenesis, and improved treatment of both conditions.
 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Keywords: Autoimmune pancreatitis; Primary sclerosing cholangitis; Immunoglobulin G4; IgG4-associated cholangitis1. Introduction
Primary sclerosing cholangitis (PSC) is a ﬁbrosclerot-
ic disease of bile ducts, in which diﬀuse stricturing of the
intrahepatic and extrahepatic biliary tree is characteris-
tically seen on cholangiography [1]. The disease is usu-
ally progressive, with death or liver transplantation
occurring a mean of 12–18 years after diagnosis [2,3].
A range of insults may induce similar cholangiographic
features to PSC, including bile duct injury, immunodeﬁ-0168-8278/$36.00  2009 European Association for the Study of the Liver.
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be diﬀerentiated on the basis of the patient’s history, and
the strong association of PSC with inﬂammatory bowel
disease [5].
Autoimmune pancreatitis (AIP) was originally
described in Japan more than 10 years ago [6], but has
only recently been recognised as a worldwide condition
[7–10]. Characteristic features include pancreatic
enlargement or a mass (which may mimic malignancy),
a raised serum IgG4 level, a lymphoplasmacytic inﬁl-
trate on biopsy, and a response to steroid therapy
[6,7]. The name is inadequate, as extrapancreatic disease
occurs in more than 45% of patients [9,11,12], and pan-
creatic disease may be minimal. Intra and extrahepatic
biliary stricturing is a particular feature in AIP [11,13–
15], which may be confused with PSC, and these biliary
changes may develop after initial presentation with pan-
creatic disease. Bjornsson et al. have recently suggested
that the biliary changes in AIP should be redesignatedPublished by Elsevier B.V. All rights reserved.
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diﬀerences in biliary abnormalities between PSC and
AIP have been reported (including longer biliary stric-
tures in AIP, with more prestenotic dilatation and asso-
ciated low bile duct stricturing [17]) these distinctions
can be subtle and making a ﬁrm diagnosis between the
two conditions based on cholangiography alone is often
diﬃcult.
We wish to outline the clinical similarities and diﬀer-
ences between these conditions, propose that some cases
previously assumed to be PSC may in fact have been
those of AIP with biliary involvement, and discuss
whether PSC and AIP/IAC are separate clinical entities
or may represent diﬀerent ends of the same disease
spectrum.
1.1. Epidemiology and relationship to chronic pancreatitis
The prevalence of PSC has been reported at approx-
imately 13 per 100,000, with a 2:1 male predominance.
AIP is also more common in males (>8:1), but no reli-
able data on prevalence exists. It has been implicated
as the cause of 6% of cases of chronic pancreatitis in
Japan, and of the pancreatic mass in 3% of pancreatico-
duodenectomies performed for suspected pancreatic
cancer [18]. Similar results have been reported from
the United States, where 11% of patients with chronic
pancreatitis were diagnosed as AIP based on the ﬁnd-
ings of pancreatic histology [19].
1.2. Inﬂammatory bowel disease, cholangiocarcinoma,
and other immune mediated diseases
Inﬂammatory bowel disease (IBD) is found in
approximately 75% of Northern European cases of
PSC, although the association is much less common in
Japan, where only 20% of PSC patients have IBD. The
majority of patients with PSC and IBD have ulcerative
colitis, although Crohn’s disease is also associated.
Whereas small series from Europe have found IBD in
approximately 30% of cases of AIP [9,12], it has been
found at very low frequency in Japanese series of AIP
[17]. Cholangiocarcinoma is a common complication
of PSC which develops in 10–30% of patients, but to
date no cases of cholangiocarcinoma complicating bile
duct involvement in AIP have been described. Other
autoimmune-type conditions, including Sjogren’s syn-
drome, thyroid disease, psoriasis, and retroperitoneal
ﬁbrosis are associated with AIP.Fig. 1. Histology from the liver hilum in a patient with complex hilar
stricturing and an associated mass. A diagnosis of IgG4-associated
cholangitis was made. (A) H + E showing extensive ﬁbrous stroma, with
associated plasma cell inﬁltrate. (B) IgG4 immunostaining showing >20
IgG4+ plasma cells per high power ﬁlm.2. Diagnostic criteria
A pancreatic mass or diﬀuse enlargement (‘sausage
pancreas’) is a diagnostic criteria for AIP, in association
with diﬀuse pancreatic duct abnormalities [6]. Whilst thepancreatic enlargement usually spontaneously resolves,
pancreatic duct abnormalities persist in the majority
not given steroid treatment [20], and pancreatic atrophy
is a common outcome. Whilst a pancreatic mass is not a
feature of classical PSC, pancreatic duct abnormalities
have been reported in 7–15% of patients [21,22] with
impaired exocrine function in 36% (although this is usu-
ally subclinical) [22].
A raised serum IgG4 was initially reported as >95%
speciﬁc and sensitive for AIP [23]. More recent data sug-
gests that although serum IgG4 is indeed highly speciﬁc in
the correct clinical setting, it is only 71–82% sensitive for
AIP [9,11]. Raised serum IgG4 levels have recently been
demonstrated in 9–36% of patients with PSC [24,25],
but are rare in other types of pancreaticobiliary disease
[25], including malignancy. High concentrations of
IgG4-positive plasma cells are found within a range of
involved tissues in AIP, including liver, kidneys, gallblad-
der, and extrahepatic bile ducts [12,26] (Fig. 1). In a recent
study of 99 patients who had undergone liver transplanta-
tion for PSC (published in abstract) [27], increased intra-
hepatic IgG4+ plasma cells were found in 23% of
explanted livers, closely correlated with a moderate-
marked periductal lymphoplasmacytic inﬁltrate.
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Both conditions are suspected of having an immune
basis, but no speciﬁc autoantibodies have been linked
to either PSC or AIP. Pericellular anti-neutrophil
cytoplasmic antibody (pANCA) is found in 70–80% of
patients with PSC [28], but it is also found in
50% of patients with type 1 autoimmune hepatitis and
30% of patients with ulcerative colitis. In contrast, it
appears to be rarely found in AIP. Antinuclear, anti-car-
bonic anhydrase and anti-lactoferrin antibodies have
been reported in the majority of Japanese patients with
AIP [29], but in a minority of patients from Europe and
USA. Several human leukocyte antigen (HLA)- and
non-HLA-associated genes have been implicated in the
development of PSC, and genetic variants on chromo-
some 6p21 seem to be important [30]. An association
of HLA DRB10405-DQB10401 haplotype in Japanese
patients with AIP has been reported [31], but susceptibil-
ity alleles among HLA class I and II antigens for AIP
have not been shown by other groups [32].
Despite the diagnostic importance of elevated serum
and tissue IgG4 in AIP/IAC (and its recent association
with PSC), the exact role of IgG4 in disease pathogene-
sis remains uncertain. Recent studies have shown that
Th2 and regulatory T cell immune reactions are
uniquely increased in AIP/IAC when compared with
other biliary diseases, including PSC [33]. This type of
pattern has also been observed in allergic disorders such
as bronchial asthma and atopic dermatitis, suggesting
that an allergic reaction may play an important part in
the pathogenesis of AIP. It has been postulated that
IgG4 plays no pathogenic role, but that it is upregulated
in response to chronic exposure to microbial [34] or non-
microbial antigens [35,36]. The recruitment of IgG4-
committed B cells (with the subsequent maintenance of
an IgG4 positive plasma cell inﬁltrate) may result from
an excessive production of anti-inﬂammatory cytokines
(e.g. TGF and IL-10) at the site of chronic inﬂammation
[35]. This might also explain why serum IgG4 levels in
AIP fall spontaneously, and in response to steroids
[23], in parallel with resolution of active inﬂammation.
It is not as yet established whether serum IgG4 levels
should be used to guide the introduction or continuation
of immunosuppression in AIP/IAC. The functioning of
IgG4 also appears to be unusual, in that IgG4 engages
the Fc (constant) portion of IgG through its own Fc,
rather than through its variable, antigen binding Fab
[37]. The relevance of this to disease remains unclear.Fig. 2. Cholangiographic response to steroid therapy in autoimmune
pancreatitis/IgG4-associated cholangitis. (A) ERCP showing complex
hilar stricture with associated intrahepatic biliary stricturing in a patient
with biliary obstruction and raised serum IgG4. The patient also had
renal impairment, focal renal abnormalities on imaging, and an IgG4+
plasma cell renal inﬁltrate. (B) Repeat ERCP 3 months following
commencement of oral steroid therapy. Marked improvement in hilar and
intrahepatic stricturing is seen.4. Response to treatment
A response to steroid therapy appears to fundamen-
tally distinguish AIP from PSC, and suggests an absence
of commonality between the conditions. No randomisedtrials of therapy in AIP/IAC have been performed, but
biliary stricturing may dramatically improve within
two months of commencing steroids [9,38,39] (Fig. 2),
and the disease course appears to be less favourable in
those who do not receive steroids [40]. In contrast, ran-
domised controlled trials of systemic and endobiliary
steroids (and other immunosuppressants) in PSC have
shown no statistical beneﬁt [41].
Table 1
Evidence for and against PSC and AIP/IAC as the same disease entity.
Evidence for Evidence against
Male predominance Weak association between
AIP & IBD
Similar cholangiographic changes No association of AIP with
cholangiocarcinoma
Associated immune-mediated diseases Diﬀerent T cell populations
Pancreatic duct stricturing Response to treatment with
steroids
Increased frequency of raised serum
and tissue IgG4 in both conditions
Pancreatic masses in AIP,
not PSC
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sise that one explanation may be the duration of disease.
In the majority of patients PSC is an indolent disease,
with established ﬁbrosclerotic changes and minimal
inﬂammatory inﬁltrate on liver biopsy at presentation,
which progresses over a period of many years. Only a
minority present with jaundice due to a benign domi-
nant extrahepatic biliary stricture. In contrast, obstruc-
tive jaundice is the presenting feature in most patients
with AIP, usually due to an intrapancreatic common
bile duct stricture associated with the pancreatic mass.
Histologically, an active lymphoplasmacytic inﬁltrate
is seen, with varying degrees of ﬁbrosis. It may be that
stricturing is reversible in these patients because the clin-
ical presentation occurs at a relatively early stage of the
inﬂammation-to-ﬁbrosis process, because of obstructive
jaundice. In the light of this theory, it is of interest that
steroids may be of beneﬁt in children with PSC [42],
although the natural history of the disease in children
appears to be diﬀerent to that seen in adults. Idiopathic
sclerosing cholangitis in children is commonly associ-
ated with a lymphocytic inﬂammatory liver inﬁltrate
(hence the proposed term autoimmune sclerosing cho-
langitis) [43]. Clinical and histological improvement in
these patients occurs in nearly 90% with immunosup-
pression. In a Norwegian review of immunosuppression
in adults with PSC, the small proportion who responded
to steroids were younger, with a shorter duration of dis-
ease, and higher pre-treatment ALT, than non-respond-
ers [44]. It is of interest that one of the earliest
descriptions of steroid beneﬁt in PSC related to a patient
with ﬂorid biliary and pancreatic duct abnormalities
[45], suggesting AIP with biliary involvement. Whilst it
may be argued that these latter two reports relate to
patients with a diﬀerent disease to PSC (i.e. overlap
PSC/autoimmune hepatitis, or ‘autoimmune sclerosing
cholangitis’) an alternative explanation is that, as with
biliary involvement in AIP, steroids were having their
beneﬁt during the early inﬂammatory phase of PSC. It
is of note that in patients with PSC, both raised serum
[24] and liver IgG4 [27] appears to be associated with
more rapid progression to liver transplantation. This
has led to a proposal, as yet unproven, that these
patients might warrant, and respond to, steroids [24].
We certainly recognise that in patients with long-stand-
ing ‘burnt-out’ AIP, serum IgG4 is normal, histology is
markedly ﬁbrosclerotic with little inﬂammatory inﬁl-
trate, and objective treatment response may be
disappointing.5. Conclusion
AIP/IAC is unlikely to be a new disease, but one that
has masqueraded as others, and has been both under-
diagnosed and in some cases wrongly labelled as PSC.Distinguishing between biliary involvement due to
AIP/IAC and classical PSC is not simply an academic
exercise, in view of the clinical improvement with ste-
roids that is seen in most patients with AIP, but not in
PSC. It is unclear whether PSC and AIP/IAC represent
completely separate conditions or variations of the same
disease spectrum (see Table 1), and further information
about the aetiology, pathogenesis, and diagnostic crite-
ria for these conditions is required. Nevertheless, emerg-
ing evidence of elevated serum and intrahepatic IgG4
levels in patients with PSC raises further questions as
to the inter-relationship between PSC and AIP/IAC,
and perhaps reinvigorates the issue of the role of immu-
nosuppression in these conditions.
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